Clinical trials - HealthQuill

AbbVie Inc.’s experimental drug has reduced the number of migraine days during the menstrual period, meeting a key goal in late-stage trials, the company announced.

AbbVie’s late-stage experimental drug reduces menstrual migraine days

HQ Team September 11, 2026: AbbVie Inc.’s experimental drug has reduced the number of migraine days during the menstrual period, meeting a key.

by HealthQuill
September 11, 2026
0 Comments

Drugs Medical Pharma

Novartis’s neuromuscular experimental drug fails to meet targets

HQ Team September 9, 2026: Novartis AG’s experimental drug to treat a neuromuscular disease failed to meet its target, the company announced. The.

by HealthQuill
September 9, 2026
0 Comments

Novartis AG will buy a US-based private biotech company, Excellergy, Inc, for $2 billion to expand its allergy portfolio.

Drugs Health Pharma

Novartis AG to acquire Exellergy for $2 billion, expand allergy portfolio

Novartis AG will buy a US-based private biotech company, Excellergy, Inc, for $2 billion to expand its allergy portfolio.

by HealthQuill
March 28, 2026
0 Comments

Pfizer Inc. and France-based Valneva SE's investigational vaccine has shown 70% efficacy in preventing Lyme disease in individuals aged five and above.

Drugs Medical Pharma

Pfizer, Valneva’s experimental Lyme disease vaccine shows 70% efficacy

HQ Team March 25, 2026: Pfizer Inc. and France-based Valneva SE‘s investigational vaccine has shown 70% efficacy in preventing Lyme disease in individuals.

by HealthQuill
March 25, 2026
0 Comments

Gilead Sciences, Inc., will acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases, for $2 billion, according to a statement.

Drugs Medical Pharma

Gilead Sciences to acquire US-based Ouro Medicines for up to $2 billion

Gilead Sciences, Inc., will acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases, for.

by HealthQuill
March 24, 2026
0 Comments

Swedish-British AstraZeneca Plc’s medicine baxdrostat lowered blood pressure in trial patients during an end-stage study, and the company plans to file for regulatory approvals by the end of the year.

Drugs Health Pharma

AstraZeneca’s medicine lowers BP, to file for early approvals

Swedish-British AstraZeneca Plc’s medicine baxdrostat lowered blood pressure in trial patients during an end-stage study, and the company plans to file for regulatory.

by HealthQuill
August 31, 2025
0 Comments

Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy failed to show “sufficient evidence” of benefit to the patients.

Drugs Health Pharma

J & J stops rheumatoid arthritis trial due to lack of ‘sufficient evidence’

Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy.

by HealthQuill
August 29, 2025
0 Comments

The Food and Drug Administration has approved Pfizer Inc.’s treatment for metastatic non-small cell lung cancer.

Drugs Health

Implant TAR-200 eliminates bladder cancer in over 80% of high-risk cases in trials

HQ Team August 18, 2025: An implant called TAR-200 has shown remarkable results in treating high-risk bladder cancer. According to a recent Phase.

by HealthQuill
August 18, 2025
0 Comments

Bristol Myers Squibb, a New Jersey-based drugmaker, announced it has met its primary goal of improved overall survival for its investigational therapy to treat liver cancer.

Uncategorized

Bayer and Kumquat Biosciences ink $1.3 billion deal to develop cancer inhibitor

HQ Team August 13, 2025: Bayer and Kumquat Biosciences, a clinical-stage biotech, announced an exclusive global license and collaboration agreement worth $1.3 billion.